tbuckley/cabot-search huggingface dataset:
The price of survival: Breast cancer patient preferences about fertility.
Authors: Amirrtha Srikanthan, Eitan Amir, Abha A. Gupta, Nancy N. Baxter, Erin Diane Kennedy
Journal: Journal of Clinical Oncology (2015)

9561 Background: Fertility is a concern for young women diagnosed with breast cancer. Concerns have been raised that women may avoid effective anti-cancer treatments to have an opportunity to preserve fertility. Here, we explore patient preferences for chemotherapy and whether women are willing to trade-off survival benefit to maintain fertility. Methods: During a standardized interview, outcomes associated with adjuvant chemotherapy and 5 years of tamoxifen (CT) or 5 years of tamoxifen alone (ET) were described to breast cancer survivors diagnosed within the past 2 years. A threshold task was performed in which each participant participated in two scenarios: (1) 10% absolute survival benefit from treatment and (2) 25% absolute survival benefit from treatment. Each participant was asked which treatment option they preferred when baseline fertility post treatment was reduced initially to 50% for both scenarios (i.e. 50% chance of conceiving naturally). If the participant indicated CT, post-treatment fertility was systematically reduced further until the participant’s preference changed from CT to ET. This threshold point represented the reduction in fertility the participant would accept before they would trade-off CT benefit. Descriptive statistics were used to characterize participants. Demographic factors (age, marital status, number of children at diagnosis and education) associated with willingness to trade-off survival benefit were evaluated with logistic regression. Results: Analysis comprised 50 women with a median age of 34.5 years (range 25-39 years). 39 (78%) women had completed university education. 34 (68%) and 45 (90%) women in scenario 1 and 2, respectively, were willing to trade-off all fertility (i.e. reduce fertility to 0% chance of conceiving naturally) in order to undertake CT and maintain survival benefits. 8 (16%) and 3 (6%) women in scenario 1 and 2, respectively, chose to not pursue CT at all in order to maintain fertility. Regression analysis did not identify any variables that were predictive of the participants’ preferences. Conclusions: Most young women with breast cancer are not willing to trade-off survival benefits of adjuvant therapy to maintain fertility.
Results of High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Chemo-Responsive Multiple Myeloma.
Authors: Kenneth A. Ault, Delvyn C. Case, Marjorie A. Boyd, Ervin J. Thomas, Frederick R. Aronson, Kurt S. Ebrahim, Jaquelyn A. Hedlund
Journal: Blood (2005)
Musculoskeletal dysfunctions associated with swimmers’ shoulder
Authors: Filip Struyf, Angela Tate, Kevin Kuppens, Stef Feijen, Lori A Michener
Journal: British Journal of Sports Medicine (2017)

Shoulder pain is the most reported area of orthopaedic injury in swimmers. The so-called 'swimmers' shoulder' has been applied to a variety of complaints involving shoulder pain in swimmers without specific reference to contributing mechanisms or structures. Knowledge of dysfunctions associated with swimmers' shoulder can assist clinicians in developing rehabilitation strategies. This literature review aims at providing clinicians insight into the musculoskeletal mechanisms and impairments associated with swimmers' shoulder that could aid them in developing rehabilitation strategies. The following musculoskeletal dysfunctions will be discussed: muscle activity, strength, endurance, muscle control, range of motion, glenohumeral laxity, glenohumeral instability, shoulder posture and scapular dyskinesis. The findings in this review may have implications for swimmers, their coaches, and rehabilitation specialists working with swimmers.
PDTB-02. COMBINATORIAL THERAPY WITH PERIFOSINE AND TOPOISOMERASE INHIBITORS SUPPRESSES DIFFUSE INTRINSIC PONTINE GLIOMA GROWTH IN VITRO
Authors: Y. Linda Wu, Raymond Chang
Journal: Neuro-Oncology (2016)

Diffuse intrinsic pontine glioma (DIPG) is the most common brainstem tumor in children and has a dismal prognosis. Thus, identifying effective chemotherapeutics is imperative. Amplifications in the receptor tyrosine kinase (RTK)/PI3K/AKT/mTOR signaling pathway have been implicated in DIPG tumorigenesis, and platelet-derived growth factor receptor (PDGFR) is the most commonly over-expressed RTK. However, inhibition of this pathway alone is insufficient due to its cytostatic effects and the activation of multiple compensatory pathways that promote tumor cell survival. This study aims to find an effective DNA-damaging chemotherapeutic agent that can be used in combination with perifosine, a PI3K/AKT inhibitor, to enhance tumor cytotoxicity and to reduce the risk of developing drug resistance. To identify an effective drug combination, patient-derived DIPG cell lines, SU-DIPG-IV and SU-DIPG-XIII, were grown in tumor stem cell media as neurospheres. Cells were treated with a combination of perifosine at its GI50 concentration and each of 26 DNA-damaging drugs at increasing concentrations. Cell viability was assayed after 72 hours of drug incubation. Initial drug screen results suggested that seven of the 26 tested chemotherapeutic agents, when in combination with perifosine, dramatically reduced cell viability in both DIPG cell lines: mitomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, actinomycin D, and cisplatin. Next, we estimated the GI50 concentrations of these drugs individually and compared the effects on cell viability of the drugs alone at their respective GI50 concentrations and in combination with perifosine at GI50. We found a greater reduction in cell viability in both DIPG cell lines when perifosine was combined with topoisomerase inhibitors daunorubicin, doxorubicin, epirubicin, and idarubicin, compared to either drug individually. We conclude that the combination of perifosine and a topoisomerase inhibitor may be a potential therapy for DIPG. Ongoing studies will further characterize the effects of this drug combination in vitro and in vivo.
Removing the Covalent Links between GP Ibα and GP Ibβ Hampers Binding of von Willebrand Factor to GP Ib-IX Complex in CHO Cells.
Authors: Xi Mo, Shi-Zhong Luo, Yuandong Peng, Adam D. Munday, Carol Sun, Michael C. Berndt, Jose A. Lopez, Jing-fei Dong, Renhao Li
Journal: Blood (2007)
Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin + Rituximab Followed by Stem Cell Transplantation in Relapsed/Refractory DLBCL Patients: Safety and Efficacy
Authors: Nina Wagner-Johnston, Andre Goy, Maria Alma Rodriguez, Christopher Ehmann, Paul Hamlin, John Radford, Catherine Thieblemont, Cheolwon Suh, John Sweetenham, Ying Jiang, Sharon T Sullivan, Erik R Vandendries, Christian Gisselbrecht
Journal: Blood (2011)
Hepatitis B Virus Reactivation in Malignant Lymphoma with Occult HBV Carrier.
Authors: Noriyasu Fukushima, Toshihiko Mizuta, Chisako Urata, Mariko Tanaka, Masako Yokoo, Masaru Ide, Takashi Hisatomi, Eisaburo Sueoka, Shinya Kimura
Journal: Blood (2009)
Cladribine (CdA) or Fludarabine (F) or High-Dose Intermittent Chlorambucil (Chl) as First-Line Treatment of Symptomatic Chronic Lymphocytic Leukemia? First Interim Analysis of Data from the International Randomized Phase III Trial.
Authors: Karin Karlsson, Mats Strömberg, Viggo Jönsson, Devinder Gill, Jens Hammerström, Jonas Wallvik, Stephen Mulligan, Kenneth Bradstock, Jan Liliemark, Gunnar Juliusson
Journal: Blood (2004)
Prospective evaluation of the impact of the 21-gene recurrence score® assay on adjuvant treatment decisions for women with node-positive breast cancer in Ontario, Canada
Authors: S. Torres, M. Trudeau, S. Gandhi, E. Warner, S. Verma, K. Pritchard, T. Petrella, E. Slodkowska, M. Hew-Shue, C. Chao, A. Eisen
Journal: Annals of Oncology (2016)
HDAC Inhibition Induces microRNA-182 Which Targets Rad51 Protein and Impairs Homologous Recombination Repair to Sensitize Cells to the Double Strand Break Inducing Nucleoside Analog, Sapacitabine in AML
Authors: Tzung-Huei Lai, Alma Zecevic, Brett Ewald, Liu Chaomei, Lara Rizzotto, Melanie Sulda, Dimitrios Papaioannou, Ramiro Garzon, William Plunkett, Deepa Sampath
Journal: Blood (2015)
Extramedullary Leukemia and Myeloid Sarcoma in AML: Results From a Population-Based Registry Study of 2261 Patients
Authors: Lene S.G. Oestgaard, Henrik Sengeloev, Mette S. Holm, Hans E. Johnsen, Marianne T. Severinsen, Eigil Kjeldsen, Olav J. Bergmann, Lone S. Friis, Morten K. Jensen, Ove J. Nielsen, Lars Kjeldsen, Jan M. Norgaard
Journal: Blood (2011)
A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)
Authors: F. André, B. Kaufman, D. Juric, E. Ciruelos, H. Iwata, I.A. Mayer, P. Conte, H.S. Rugo, S. Loibl, G. Rubovszky, H. Tesch, K. Inoue, Y.-S. Lu, L. Ryvo, A.-S. Longin, D. Mills, C. Wilke, C. Germa, M. Campone
Journal: Annals of Oncology (2016)
Detection and management of everolimus associated pneumonitis with serum markers for interstitial pneumonia
Authors: Nahomi Tokudome, Hiroki Ueda, Masanori Nakanishi, Atsushi Hayata, Hiroaki Akamatsu, Ayaka Tanaka, Yasuhiro Koh, Takashi Kikuchi, Keiichiroh Akamatsu, Nobuyuki Yamamoto
Journal: Annals of Oncology (2016)
396PD IL-2 synergizes with PD-1/PD-L1 blockade via CD28/CHK1 pathway to enhance CD81 T cell responses in lung squamous cell carcinoma
Authors: S.-M. Huang, S.-P. Wu, R.-Q. Liao, Z.-Y. Dong, H. Tu, Z. Xie, J. Su, J.-J. Yang, X. Zhang, Y.-L. Wu
Journal: Annals of Oncology (2016)
α-Lipoic acid treatment prevents cystine urolithiasis in a mouse model of cystinuria
Authors: Tiffany Zee, Neelanjan Bose, Jarcy Zee, Jennifer N Beck, See Yang, Jaspreet Parihar, Min Yang, Sruthi Damodar, David Hall, Monique N O'Leary, Arvind Ramanathan, Roy R Gerona, David W Killilea, Thomas Chi, Jay Tischfield, Amrik Sahota, Arnold Kahn, Marshall L Stoller, Pankaj Kapahi
Journal: Nature Medicine (2017)
Comparison of adjuvant chemoradiation to peri-operative chemotherapy for the treatment of resected gastric and gastroesophageal junction adenocarincoma.
Authors: Hae Rin Kim, Christian K. Kollmannsberger, Devin Schellenberg, Winson Cheung, Howard John Lim
Journal: Journal of Clinical Oncology (2012)

e14537 Background: Currently there are several accepted peri-operative treatment modalities for the resected gastric (GC) and gastroesophageal junction (GEJ) adenocarcinoma. In the 2008, peri-operative chemotherapy (CRT) using the MAGIC was adopted as the preferred approach to adjuvant chemoradiation with the MacDonald protocol (cXRT) in the British Columbia. An era to era comparison was performed to determine if there were differences in outcomes. Methods: Data from the pharmacy records of patients (pts) referred to 1 of 5 cancer treatment in BC were analyzed from 2001- July 2010. Pts that underwent curative resection for GC or GEJ were only included. cXRT cohort was defined from Jan 2001-Dec 2007, prior to the CRT era. CRT cohort started from Jan 2008-July 2010. Descriptive statistics were used to compare the groups. Survival analysis was performed using Kaplan Meier methods. Results: Table 1 summarizes the patient characteristics. In the CRT arm, there were more males, less pts with a LN ratio &gt;0.2 and shorter median follow-up. 92.1% completed the pre-op chemotherapy and 44.7% completed post-op chemotherapy whereas 73.3% of pts completed cXRT (p&lt;0.05). 1 yr survival was similar between the 2 cohorts. Median overall survival was not reached in the CRT arm and was 64.1 months in the cXRT arm. Conclusions: Delivery of CRT was similar to that in the MAGIC trial. Outcomes of CRT compared to cXRT appears to be similar in this cohort to cohort study with similar 1 yr survival. Pre-operative CRT results in less pts with a LN ratio &gt; 0.2. Further follow-up is needed with respect to relapse and overall survival. Either modality can be considered for peri-operative management of GC or GEJ adenocarcinoma. [Table: see text]
Telomerase Gene Complex Mutations Are Common in Myelodysplastic Syndromes Patients
Authors: Mariam Ibañez, Jie Jiang, Shreyans Gandhi, Mian Syed, Alexander E Smith, Steve Best, Nicholas Lea, Azim M Mohamedali, Momin Ahmed, Judith C. W. Marsh, Austin G Kulasekararaj, Ghulam J Mufti
Journal: Blood (2014)
Abstract P212: Haploinsufficiency of Target of Rapamycin Attenuates Different Forms of Cardiomyopathies in Adult Zebrafish
Authors: Xiaojing Sun, Yonghe Ding, Wei Huang, Tiffany Hoage, Margaret Redfield, Sudhir Kushwaha, Sridhar Sivasubbu, Xueying Lin, Stephen Ekker, Xiaolei Xu
Journal: Circulation Research (2011)

In contrast to the wide application of zebrafish embryos in developmental genetic studies, the value of an adult zebrafish to dissect signaling pathways in human diseases such as cardiomyopathy remains largely elusive. Previously, we have established anemic tr265/tr265 fish as the first adult zebrafish model of cardiomyopathy. Here, we generate the second adult zebrafish cardiomyopathy model induced by injection of a single bolus of doxorubicin (DOX). Despite their different pathogenesis, cardiac enlargement induced by either anemia or DOX can be effectively attenuated by inhibition of target of rapamycin (TOR) signaling via rapamycin treatment. However, along the progression of both models, we have also detected dynamic TOR activity and distinct effects of TOR signaling inhibition at different stages of pathogenesis. To assess the long term effects of TOR haploinsufficiency, we utilized a zebrafish target of rapamycin (ztor) mutant that was identified from a mutagenesis screen. We show that sustained TOR inhibition in ztor/+ improved cardiac function, prevented pathological remodeling events, and ultimately reduced mortality in both adult fish models of cardiomyopathy. Mechanistically, these cardioprotective effects are conveyed by the anti-hypertrophy, anti-apoptosis, and pro-autophagy function of TOR signaling inhibition. Together, our results prove adult zebrafish as a novel vertebrate model for human cardiomyopathies and provide genetic evidences for a cardioprotective function of TOR signaling inhibition in different forms of cardiomyopathies.
Single arm, multicentre, non-randomized open-label trial to evaluate the safety of eribulin in third line chemotherapy in patients with HER2-negative metastatic or locally advanced breast cancer previously treated with anthracyclines and taxanes: Onsite study (ONCOSUR 2012-02)
Authors: L.M. Manso Sánchez, F. Moreno Antón, Y. Izarzugaza Perón, J. Ilgado De Mingorance, P. Borrega, M.J. Echarri González, N. Martínez, A. López González, C. Olier, A. Ballesteros García, I. Chacón, E. Ciruelos, J.A. García-Sáenz, L. Paz-Ares
Journal: Annals of Oncology (2016)
Identification and Hematopoietic Potential of CD45-Negative Clonal Cells with Very Immature Phenotype (CD45−CD34−CD38−Lin−) in Patients with Myelodysplastic Syndromes.
Authors: Kiyoyuki Ogata, Chikako Satoh, Mikiko Tachibana, Hideya Hyodo, Hideto Tamura, Kazuo Dan, Takafumi Kimura, Yoshiaki Sonoda, Takashi Tsuji
Journal: Blood (2004)
IgG and IgA Monoclonal Gammopathies of Undetermined Significance (MGUS) at Low Risk of Evolution: Proposal and Validation of a Prognostic Scoring System
Authors: Francesca Gaia Rossi, Luigi Marcheselli, Maria Teresa Petrucci, Davide Rossi, Vincenzo Callea, Andrea Guffanti, Marianna De Muro, Vincenzo Federico, Anna Baraldi, Pellegrino Musto, Andrea Bacigalupo, Gianluca Gaidano, Maria Goldaniga, Giuseppe Avvisati, Giorgio Lambertenghi Deliliers, Luca Baldini
Journal: Blood (2008)
PRAME-Specific CD8+ T Cells Are Spontaneously Present in a Large Proportion of Healthy Donors and Leukemic HLA-A0201 Patients.
Authors: Katayoun Rezvani, Abdul Tawab, Yasemin Kilical, Giuseppe Sconocchia, Jonming Li, Nancy Hensel, Roger Kurlander, John Barrett
Journal: Blood (2004)
Analysis of clinical characteristics in breast cancer patients with the Japanese founder mutation of <i>BRCA1</i> L63X.
Authors: Reiko Yoshida, Mayuko Inuzuka, Tomoko Watanabe, Junko Yotsumoto, Takashi Kuwayama, Terumasa Sawada, Sadako Akashi-Tanaka, Seigo Nakamura
Journal: Journal of Clinical Oncology (2015)

22 Background: Hereditary breast and ovarian cancer (HBOC) is a high-penetrance inherited disease, and founder mutation has been reported in the West. However, there are yet no reports of founder mutation of HBOC on breast cancer in the Japanese population. In this study, we report the breast cancer clinical characteristics of L63X, which is one of the founder mutations in BRCA1 in the Japanese population. Methods: Data on 223 affected breast cancer patients (28 BRCA1 carriers, 19 BRCA2 carriers, and 176 non-carriers) were collected at Showa University in Tokyo from September 2010 to June 2015. In 22 independent mutations of BRCA1, the L63X mutation was detected in 9 patients. Data regarding the age of breast cancer onset, pathological features, clinical features, and family history were collected. Results: The age of onset was no significant differences between the L63X mutation and other BRCA1 mutations (39.7 vs. 38.5years). The proportion of triple negative breast cancer patients was 87.5% in the L63X mutation carriers and 89.5% in other BRCA1 mutation carriers. No patients of the L63X affected bilateral breast cancers. On the other hand, 36.7% of other BRCA1mutations affected bilateral breast cancers. There was no significant difference in pathological features (intrinsic subtype, nuclear grade and ki-67 index). The L63X carriers tended to have a family history of breast cancers. All L63X mutations were detected in the Eastern part of Japan. Conclusions: The breast cancer clinical characteristics of L63X might be considered no different from other types of BRCA1 mutations. Recently, it has been reported that breast and ovarian cancer risks varied according to the type and location of BRCA1/2 mutations. L63X mutation is located in the breast cancer cluster region in BRCA1. Further investigation is necessary for appropriate validation and accumulation of data.
Phase Ib Study of Recombinant Circularly Permuted TRAIL (CPT) in Relapsed or Refractory multiple Myeloma Patients
Authors: Wenming Chen, Lugui Qiu, Jian Hou, Xuejun Zhang, Xiaoyan Ke, Zhao Wang, Fang Zhou, Shifang Yang, Yaozhong Zhao, Yun Leng, Hao Xi, Fuxu Wang, Bing Zhu
Journal: Blood (2012)
P06.03 Anaplastic oligodendroglioma and oligoastrocytoma without 1p-19q co-deletion: a mono-institutional retrospective study
Authors: A. Silvani, P. Gaviani
Journal: Neuro-Oncology (2016)

AbstractAllelic losses of chromosomes 1p and 19q in patients with anaplastic oligodendroglioma(AOD) and oligoastrocytoma(AOA) represent a strong prognostic factor and a powerful predictor of survival. These subset of patients benefit from the addition of chemotherapy(CT) to radiotherapy(RT), with a significant improvement of overall survival (OS) and progression-free survival (PFS). In patients without 1p19q co-deletion, there are no standard-of-care and conflicting opinions impose to review the possible therapeutic approach. A total of 214 patients with histological proven of AOD and AOA treated in our Institution over the last 10 years were evaluated. Eighty patients were eligible for loss-of-heterozigosity (LOH) evaluation. The absence of 1p19q co-deletion was confirmed in 33 patients. Clinical and genetic data, treatments and survival assessment were described and discussed. In non co-deleted group, m-OS and m-PFS were respectively 38,4 months (95% CI 21,99-59,77) (P=0,018) and 16 months (95% CI 13,0-20,0). On the other hand, m-OS of the whole group was 59.7 months. Concerning treatments, therapeutic approach has been variable with a higher percentage in RT and concomitant temozolomide in the past two years. In 6% of patients CT was considered as first-line treatment after surgery. Data confirmed the prognostic role of LOH, with the most advantages for patients with co-deletion. Regarding therapeutic approaches, results show a quite aggressive attitude in our clinical practice. The choice between RT or CT as first line treatment after surgery do not seem to influence the prognosis.
Efficacy and Safety of Reduced Dose Intensity R-CHOP in Elderly Patients with Diffuse Large B Cell Lymphoma
Authors: Jungmin Jo, Dok Hyun Yoon, Sang-wook Lee, Chan-Sik Park, Jooryung Huh, Kyoungmin Lee, Eun Hee Kang, Shin Kim, Cheolwon Suh
Journal: Blood (2012)
Arginine Metabolite Profiling in Sickle Cell Disease: Abnormal Levels and Correlations with Pulmonary Hypertension, Desaturation, Hemolysis and Organ Dysfunction.
Authors: Gregory J. Kato, Wang Zeneng, James G. Taylor, Roberto F. Machado, William C. Blackwelder, Mark T. Gladwin, Stanley L. Hazen
Journal: Blood (2006)
Elevated expression of Erbin destabilizes ERα protein and promotes tumorigenesis in hepatocellular carcinoma
Authors: Hua Wu, Su Yao, Shen Zhang, Jing-Ru Wang, Peng-Da Guo, Xiu-Ming Li, Wen-Juan Gan, Lin Mei, Tian-Ming Gao, Jian-Ming Li
Journal: Journal of Hepatology (2017)
Diagnosing Sinusitis
Authors: Alvah R. Cass
Journal: Annals of Internal Medicine (1993)

Letters1 July 1993Diagnosing SinusitisAlvah R. Cass, MD, Scott B. Cantor, PhD, and Richard D. Clover, MDAlvah R. Cass, MDThe University of Texas Medical Branch at Galveston; Galveston, TX 77555-0853Search for more papers by this author, Scott B. Cantor, PhDThe University of Texas Medical Branch at Galveston; Galveston, TX 77555-0853Search for more papers by this author, and Richard D. Clover, MDThe University of Texas Medical Branch at Galveston; Galveston, TX 77555-0853Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-119-1-199307010-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Williams and colleagues [1] concluded that five clinical findings can help predict the probability of sinusitis for a male patient experiencing sinus symptoms. Their methods carefully avoided verification and expectation biases and measured observer agreement. However the generalizability of the study results is more restricted than the authors suggest. Men with a median age of 50 years enrolled from a university-affiliated Veterans Affairs medical center are not representative of a general medical or primary care population.The study's prevalence of 38% is much higher than that in one epidemiologic study where sinusitis complicated 0.5% of upper respiratory ...References1. Williams JW Jr, Simel DL, Roberts L, Samsa GP. Clinical evaluation of sinusitis: making the diagnosis by history and physical examination. Ann Intern Med. 1992; 117:705-10. Google Scholar2. Dingle JH, Badger GF, Jordan WS Jr. Illnesses in the home: a study of 25,000 illnesses in a group of Cleveland families. Cleveland, Ohio: The Press of Western Reserve University; 1964:292. Google Scholar3. Savolainen S. Allergy in patients with acute maxillary sinusitis. Allergy. 1989; 44:116-22. Google Scholar4. Pelikan Z, Pelikan-Filipec M. Role of nasal allergy in chronic maxillary sinusitis: diagnostic value of nasal challenge with allergen. J Allergy Clin Immunol. 1990; 86:484-91. Google Scholar5. Wasson JJ, Sox HC, Neff RK, Goldman L. Clinical prediction rules: applications and methodological standards. N Engl J Med. 1985; 313: 793-9. Google Scholar Author, Article, and Disclosure InformationAffiliations: The University of Texas Medical Branch at Galveston; Galveston, TX 77555-0853 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 July 1993Volume 119, Issue 1Page: 92KeywordsAllergensAllergic rhinitisEpidemiologyMotivationUpper respiratory tract infections Issue Published: 1 July 1993 CopyrightCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Final results of a phase II study of oral vinorelbine (NVBo) monotherapy in patients (pts) with advanced EGFR-positive non-small-cell lung cancer (NSCLC) after failure of EGFR-TKI in first line (NAVoTRIAL 2)
Authors: E.-H. Tan, G. Banna, R. Ramlau, G. Ceresoli, A. Camerini, J. Milanowski, M. Caruso, P. Landreau, J.-C. Vedovato, D. Kowalski
Journal: Annals of Oncology (2016)